Loading quotes...

Forecast

The analysts' average price target is €31.45 (+94.98%). The median is €30.83 (+91.13%).

Buy	11
Hold	2
Sell	1

News Go to news feed

Dyne Therapeutics prepares launches for DMD and DM1, PDUFA for DYNE-101 in January 2024

At the Morgan Stanley conference, Dyne Therapeutics outlined its commercialization preparations: a PDUFA decision for DYNE-101 in DMD exon 51 is scheduled for January 2024, and the launch for DM1 (Basivarsen) is planned for 2025. The company emphasizes pro forma liquidity of $1.3 billion and a capital-efficient infrastructure to support simultaneous launches of multiple products. Dyne highlights the FORCE platform, which delivers oligonucleotide therapeutics selectively to muscle and partly CNS tissues, and reports encouraging functional data in DMD and DM1. Key risks remain regulatory decisions, reimbursement, and scaling manufacturing; additional data points (ACHIEVE expansion, 12-month data, HARMONIA recruitment) are expected in the coming quarters. » More on de.investing.com
Dyne Therapeutics outlines market launch of Z-Rostudirsen and Z-Basivarsen and bolsters pipeline

At the Cantor conference, Dyne Therapeutics announced plans to commercialize two lead programs: Z-Rostudirsen (PDUFA Jan. 21) for Duchenne muscular dystrophy and Z-Basivarsen for myotonic dystrophy type 1. The FORCE platform is intended to enable deep tissue and CNS distribution and serves as a differentiator. Pro-forma cash of $1.3 billion secures operations through the second quarter of 2028 and supports building commercial, manufacturing and further development capabilities. Dyne is pursuing a two-pronged approval strategy for DM1 while simultaneously expanding its DMD exon-skipping programs. » More on de.investing.com
Dyne Therapeutics falls 31% pre-market after unconfirmed trigger

Dyne Therapeutics' stock plunged 31.0% to $16.76 in pre-market trading, with no official company statement yet explaining the reason. The sharp drop points to a company-specific negative event in the regulatory, clinical, or product-pipeline area. Relevant upcoming events include a PDUFA decision for z-rostudirsen (DYNE-251) on January 21, 2027, and topline data for the expansion cohort of z-basivarsen in Q1 2027. Dyne also reported a larger quarterly loss of about $178.6 million (loss/share -$1.08) versus consensus -$0.75, while the broader market showed no comparable move. » More on de.investing.com

Financials

In the last quarter, DYNE THERAPEUTICS DL-0001 had revenue of €0 and net profit of -€156.45m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-156.45m	66.34%
EBITDA	-151.94m	62.42%

Fundamentals

Metric	Value
Market capitalization	€2.78bn
Number of shares	186.75m
52-week high/low	€24.40 - €12.51
Dividends	No
Beta	1.12
P/E ratio	-5.01
PEG ratio	-0.35
P/B ratio	3.93
P/S ratio	0.00

Company profile

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..